Second drug targeting KRASG12C shows benefit in mutated non-small-cell lung cancer
Clinical activity with a second drug inhibiting KRASG12C confirms its role as a therapeutic target…
Browsing: ELCC 2021
ELCC 2021: More than one in 10 patients with lung cancer do not know what type they have
More than one in 10 patients with lung cancer do not know what type of…